KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $425000.0.

  • TherapeuticsMD's Change in Accured Expenses rose 19929.58% to $425000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$182000.0, marking a year-over-year increase of 9557.18%. This contributed to the annual value of -$1.0 million for FY2024, which is 9359.77% up from last year.
  • TherapeuticsMD's Change in Accured Expenses amounted to $425000.0 in Q3 2025, which was up 19929.58% from -$190000.0 recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Change in Accured Expenses peaked at $19.1 million during Q3 2022, and registered a low of -$14.1 million during Q4 2022.
  • Over the past 5 years, TherapeuticsMD's median Change in Accured Expenses value was -$190000.0 (recorded in 2025), while the average stood at -$384684.2.
  • As far as peak fluctuations go, TherapeuticsMD's Change in Accured Expenses soared by 328226.95% in 2022, and later crashed by 33181.82% in 2025.
  • Over the past 5 years, TherapeuticsMD's Change in Accured Expenses (Quarter) stood at -$8.9 million in 2021, then tumbled by 58.77% to -$14.1 million in 2022, then skyrocketed by 73.04% to -$3.8 million in 2023, then skyrocketed by 81.79% to -$691000.0 in 2024, then soared by 161.51% to $425000.0 in 2025.
  • Its Change in Accured Expenses stands at $425000.0 for Q3 2025, versus -$190000.0 for Q2 2025 and $274000.0 for Q1 2025.